March 2009 Volume 6 Number 3
Visit Nature Clinical Practice Oncology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=40&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
================ Important information - please read ================
Note: Starting with the April 2009 e-Alert, Nature Clinical Practice
Oncology will change its name to Nature Reviews Clinical Oncology.
No action is required on your part; you will continue to receive this
e-Alert each month. However, in compliance with our data protection
practices, we need to inform you that the sender's email address will
change from NCP_Oncology@ealert.nature.com to
Nature_Reviews_Clinical_Oncology@ealert.nature.com
=====================================================================
The next issue of Nature Clinical Practice Oncology will be Nature
Reviews Clinical Oncology.
Beginning with the April issue, Nature Clinical Practice Oncology will
be renamed Nature Reviews Clinical Oncology and introduce an updated
look with additional content.
For more information visit
http://links.ealert.nature.com/ctt?kn=7&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
Targeting EGFR in head and neck cancer: a decade of progress
Chris Boshoff and Marshall Posner
http://links.ealert.nature.com/ctt?kn=8&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Gene-expression signatures predict survival in patients with DLBCL
http://links.ealert.nature.com/ctt?kn=13&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Mohs surgery is superior to excision for recurrent facial BCC
http://links.ealert.nature.com/ctt?kn=34&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Exon 11 KIT genotype improves outcome in imatinib treated GIST
http://links.ealert.nature.com/ctt?kn=72&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
HER2 and EGFR status and correlation with response to lapatinib and
chemotherapy
http://links.ealert.nature.com/ctt?kn=15&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
COX2 and EGFR variants that predict survival in colorectal cancer
http://links.ealert.nature.com/ctt?kn=52&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Tumor-specific allogeneic T cells treat solid tumors in mice
http://links.ealert.nature.com/ctt?kn=14&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Improved quality of life after treatment with amifostine for NSCLC
http://links.ealert.nature.com/ctt?kn=35&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Vasomotor or joint symptoms as a marker of endocrine response in breast
cancer
http://links.ealert.nature.com/ctt?kn=75&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Lenalidomide and dexamethasone improve outcome in multiple myeloma
http://links.ealert.nature.com/ctt?kn=39&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
----------------------
PRACTICE POINTS
----------------------
Optimal timing of surgery after preoperative chemoradiotherapy for rectal
cancer
Lars Pahlman
http://links.ealert.nature.com/ctt?kn=46&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Fludarabine, cyclophosphamide and rituximab for chronic lymphocytic
leukemia: no country for old men?
Terry J Hamblin
http://links.ealert.nature.com/ctt?kn=31&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Cetuximab therapy for patients with advanced squamous cell carcinomas
of the head and neck
William N William Jr, Edward S Kim and Roy S Herbst
http://links.ealert.nature.com/ctt?kn=11&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Should irinotecan or etoposide be used in combination with carboplatin
for small cell lung cancer?
Alexander Schmittel and Ulrich Keilholz
http://links.ealert.nature.com/ctt?kn=1&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
----------------------
VIEWPOINT
----------------------
Mammography in developing countries: the risks associated with globalizing
the experiences of the Western world
Alan A Arslan and Silvia C Formenti
http://links.ealert.nature.com/ctt?kn=70&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Xoft Axxent[reg] electronic brachytherapy-a new device for delivering
brachytherapy to the breast
Adam Dickler
http://links.ealert.nature.com/ctt?kn=24&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Treatment of advanced disease in patients with well-differentiated
neuroendocrine tumors
Diane L Reidy, Laura H Tang and Leonard B Saltz
http://links.ealert.nature.com/ctt?kn=45&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Pharmacogenomic progress in individualized dosing of key drugs for
cancer patients
Christine M Walko and Howard McLeod
http://links.ealert.nature.com/ctt?kn=37&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
Effect of bisphosphonates on pain and quality of life in patients with
bone metastases
Luis Costa and Pierre P Major
http://links.ealert.nature.com/ctt?kn=38&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Unintended pregnancy during radiotherapy for cancer
Saskia N de Wildt, Nobuko Taguchi and Gideon Koren
http://links.ealert.nature.com/ctt?kn=59&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
----------------------
CORRIGENDUM
----------------------
Drug Insight: gastrointestinal and hepatic adverse effects of
molecular-targeted agents in cancer therapy
Yohann Loriot, Gabriel Perlemuter, David Malka, Frederique Penault-Llorca,
Valerie Boige, Eric Deutsch, Christophe Massard, Jean Pierre Armand
and Jean-Charles Soria
http://links.ealert.nature.com/ctt?kn=71&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
----------------------
ARTICLE RESPONSES
----------------------
Precancerous lesions of the breast
Fattaneh A Tavassoli and Donald R Lannin
http://links.ealert.nature.com/ctt?kn=28&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
The clinical trials system is broken
Sandra Buckner
http://links.ealert.nature.com/ctt?kn=6&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=26&m=31762034&r=MTc2NDg2OTc4MQS2&b=2&j=NDYxNjk1MDUS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
=====================================================================
